By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


bluebird bio 

840 Memorial Drive

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-491-5601 Fax: 617-576-2421


Key Statistics

Ownership: Public

Web Site: bluebird bio
Symbol: BLUE


Gene Therapy

Company News
bluebird bio (BLUE) Announces Collaboration With Duke University’s Robert J. Margolis, MD, Center For Health Policy On Value-Based Payment Framework For Gene Therapy 5/23/2017 9:58:11 AM
bluebird bio (BLUE) To Present New Data From Lentiglobintm Clinical Studies At European Hematology Association (EHA) Annual Meeting 5/18/2017 7:36:14 AM
bluebird bio (BLUE) Reports First Quarter 2017 Financial Results And Recent Operational Progress 5/4/2017 7:10:42 AM
bluebird bio (BLUE) Enters Lentiviral Vector Patent License Agreement With GlaxoSmithKline (GSK) For Commercialization Of Gene Therapies 5/2/2017 7:54:52 AM
bluebird bio (BLUE) Licenses Lentiviral Vector Patent Rights For Development And Commercialization Of Cell Therapies 5/2/2017 7:52:30 AM
bluebird bio (BLUE) Appoints New Senior Manufacturing And Corporate Development Executives 3/20/2017 6:54:12 AM
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017 6:56:44 AM
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017 5:44:53 AM
bluebird bio (BLUE) Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Progress 2/23/2017 7:17:10 AM
bluebird bio (BLUE) Announces First Patient Treated With Lentiglobintm Drug Product Under Amended Study Protocol In HGB-206 Phase I Study Of Patients With Severe Sickle Cell Disease 2/3/2017 8:19:21 AM